RxDoctor Payments Data

Brian Levin, MD

Urology · Westminster, MDNPI 1164479507

Payments from drug & device makers

$7,891in general payments, 2019–2025

Across 379 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$822
  • Teleflex LLC$793
  • Olympus America Inc.$662
  • Astellas Pharma US Inc$599
  • Endo Pharmaceuticals Inc.$432
  • Urogen Pharma, Inc.$350
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,82599%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,891 in reported general payments places this provider in the 60th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$569,414
Medicare patients
1,335
Services billed
34,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide21$282,948
GemtesaVibegron207$226,995
OrgovyxRelugolix31$104,056
MyrbetriqMirabegron92$91,452
XyostedTestosterone Enanthate20$18,250
Tamsulosin Hcl906$17,600
Dutasteride226$12,512
Methenamine Hippurate95$12,157
Potassium Citrate ErPotassium Citrate94$7,943
Testosterone49$7,826
Tadalafil23$5,813
Tolterodine Tartrate ErTolterodine Tartrate82$5,580
Fesoterodine Fumarate ErFesoterodine Fumarate54$5,012
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl16$4,575
Solifenacin Succinate25$3,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$599$374,400113 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$822$331,051238 claims
Antares Pharma, Inc.Xyosted$195$18,25020 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$13$1,50511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 274 urology providers in Maryland.

Other urology in Westminster

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →